Off label use of rituximab at a tertiary neurology centre

<h3></h3> Rituximab (RTX) is approved for use at Imperial College Healthcare NHS Trust (ICHNT) via the Advanced Immunotherapies MDT (AIM) for a range of neurological conditions with a record of expected outcomes of treatment required. Aim to assess the adherence to local policies and NHSE commissioning criteria for the use of RTX. <h3>Methods</h3> Retrospective audit of subjects between April 22 &amp; June 23 for commissioned indications who had approved funding applications for RTX. <h3>Results</h3> Indication was documented for 100% of patients, 53% had documentation of intended treatment duration 86% had a follow up arranged. 51 doses of RTX were issued for 37 patients for 7 indications (15 Myasthenia Gravis, 11 neuropathies , 4 myositis , 3 Autoimmune Encephalitis , 2 sarcoid ,1 Transverse Myelitis,1 CNS vasculitis). 25 were for indications not commissioned by NHSE; 23 were commissioned but did not have a Blueteq submission and Blueteq funding submissions were completed for 3. For the 23 indications without submissions there was not enough documentation to determine eligibility. Total expenditure on RTX was £26K, £14.5K of this was for indications funded by NHSE. <h3>Conclusion</h3> AIM meeting allows a structured approach to giving RTX. A significant number of indications are now commissioned by NHSE